Granules India and Ajinomoto OmniChem create jv in India
Granules OmniChem will operate an API and intermediates facility in Vishakhapatnam, Andhra Pradesh
The new company, Granules-OmniChem, will build a US$20m plant in the Pharmacity SEZ zone in Vishakhapatnam, Andhra Pradesh, initially to manufacture high-value, low-volume APIs and intermediates.
Construction of the facility will start in November and should be completed towards the end of 2012.
The jv aims to capitalise on demand from pharmaceutical firms which are outsourcing their manufacturing needs at a time when the industry is focused on the US$234bn generics market. More than 80% of API production is for the generics market.
Granules-Omnichem will focus on producing APIs and intermediates for existing customers of both partners and in the future manufacture new chemical entities.
‘Our shareholders will benefit since this will enable Granules to diversify its business by offering high value APIs and intermediates which will increase our profitability,’ said Krishna Prasad, managing director of Granules.
Gwin Bompas, managing director of Ajinomoto OmniChem, which employs around 700 people at three sites in Belgium, said the jv would enable the firm to ‘offer access to quality medicine at an affordable price for the market’.
Granules India manufactures finished dosage forms, pharmaceutical intermediates and APIs, which are distributed in more than 50 countries.
You may also like
Trending Articles
You may also like
Manufacturing
Pharmaceutical labelling in focus at Interpack 2026
Well prepared for new requirements. The upcoming reform of EU pharmaceutical legislation is expected to bring stricter requirements for traceability and labelling. The new 152E HC wrap-around labelling machine, developed specifically for contract packers, covers a wide product range with minimal change parts. Also on display: specialised labelling machines for automated product handling of small batches and high-speed labelling applications.
Manufacturing
Virica Biotech and FUJIFILM Biosciences collaborate to boost AAV vector yields in HEK293 manufacturing system
Virica Biotech has announced a collaboration with FUJIFILM Biosciences to co-develop an off-the-shelf enhancer-media solution combining Virica's VSE technology with FUJIFILM's BalanCD HEK293 system, targeting improved AAV productivity and process robustness for gene therapy manufacturers
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Accelerating the development of bispecific antibodies
Sherry Gu, Executive Vice President and CTO at WuXi Biologics, explains how the use of comprehensive tailored approaches can enhance bispecific antibody productivity, stability and quality while accelerating their delivery to market